Mobile Stroke Unit (MSU): The Future of Acute Stroke Treatment?
Journal Title: Neuro – Open Journal - Year 2016, Vol 3, Issue 1
Abstract
Time is the key factor in brain survivability in acute stroke treatment.1The therapeutic effects of intravenous recombinant tissue Plasminogen Activator (IV rtPA) are highly dependent on time.1-3 Stroke patients presenting within the first 60 minutes, or the golden hour, are the most likely to benefit from recanalization therapy.1-3 Thus, making rapid clinical and imaging evaluation of stroke patients of upmost importance and very difficult to complete within the golden hour time window. Based on Get with the Guidelines-Stroke Program (April 2003 to October 2009), less than one-third of patients treated with IV rtPA have door-to-needle times of less than 60 minutes.
Authors and Affiliations
Waldo R. Guerrero
Keywords
Related Articles
- EP ID EP552535
- DOI 10.17140/NOJ-3-e005
- Views 126
- Downloads 0
Astrocyte: A Potential Target for the Treatment of Anorexia Nervosa
Without homeostatic control of feeding behavior, energy balance will be disturbed towards either energy surfeit or deficit, respectively, leading to obesity or wasting. Anorexia Nervosa (AN) is a disorder characterized w...
The Diagnostic Role of Neuromuscular Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy
The immune-neuropathies are a heterogenous group of peripheral nerve disorders. Their diagnostic classification is mainly based on the documentation of the distribution pattern of peripheral nerve impairment and the resu...
Neurovascular Conflicts of Cerebellopontine Angle: A Review of the Literature
The pathology of the cistern of the cerebellopontine angle is primarily the disease of the nervous and vascular structures that it contains and of the meninges that line it. It appears by the Trigeminal Neuralgia (TN), H...
Mobile Stroke Unit (MSU): The Future of Acute Stroke Treatment?
Time is the key factor in brain survivability in acute stroke treatment.1The therapeutic effects of intravenous recombinant tissue Plasminogen Activator (IV rtPA) are highly dependent on time.1-3 Stroke patients presenti...
Targeting Calcitonin Gene-Related Peptide and its Receptor by Monoclonal Antibody, New Developments in the Prevention of Migraine
Migraine is a chronic headache disorder with an unknown pathophysiology. Research in the past decade has shown that to be a brain disorder, a dismodulation of sensory processing affecting vascular tone and pain1-3 but si...